Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials

This cross-sectional study compares US Food and Drug Administration–approved anticancer “me-too,” or next-in-class, drugs with randomized clinical trial comparators of first-in-class drugs.